the field of leprosy and disability in 16 leprosy endemic countries. Each year,
around 219.000 people globally are diagnosed with leprosy. Indonesia ranks
number 3, with relatively high disability rates. NLR, with its International
Office in Amsterdam, has been supporting projects in Indonesia since 1967. The
main partner of NLR Indonesia is the Ministry of Health (MoH) and activities
are aligned to MoH policies and priorities. At provincial level, the Leprosy
Control Program Technical Advisors (LCTAs) are strengthening the capacity of
the provincial and districts government’s health staff to improve the quality of
leprosy services. Next to supporting leprosy control, NLR Indonesia’s Inclusion
and Disability program aims to support and advance holistic, community-based
rehabilitation and sustainable inclusive development for persons with
disabilities, including children with disabilities and people affected by
e.g. single-dose of rifampicin (SDR) have been shown to be effective as
post-exposure prophylaxis (PEP) in contacts of leprosy patients. It is expected
to be sufficiently bactericidal to treat people with sub-clinical leprosy
infection. It is not found to be very effective in close contacts hence an
effective additional strategy is screening of contacts of new cases using an
immunological screening test and giving those testing positive an enhanced
prophylaxis with two antibiotics and the intervention is known as PEP++, while
the others who are not positive receive a single dose of rifampicin.
on 2017, NLR will implement the PEP++ in 3 highest leprosy endemic countries
(India, Brazil and Indonesia). In Indonesia, the five-years project will be
implemented in two districts of East Java. Our dream is to stop
transmission of leprosy with objectives are to achieve early detection and
preventive treatment of leprosy-infected people before symptoms appear, to
provide and to disseminate evidence of the effectiveness of the Stop
Transmission approach to relevant stakeholders.
looking for the full-time position of: Program Support & Investigation Officer
PEP++ Program Support & Investigation Officer will carry out his
or her own research needed to fulfill the criteria for a PhD at the Erasmus
Medical Centre (ErMC). The details of the research tasks will vary for each PhD
topic. S/he reports to the PEP++ Project Coordinator. S/he assists the PEP++
Project Coordinator in coordinating all field research of the PEP++ research
project. S/he liaises with the Academic Supervisor (promotor) and co-promotor
at ErMC, and with the Principal Investigator in his/her own country. S/he also
liaises with the PEP++ PhD candidates based elsewhere regarding the division of
research tasks, data collection and management.
in the project implementation.
closely with the partner organisation(s)/departments through whom the project
is carried out.
annual plans for own (PhD) activities in the PEP++ Project.
annual budgets for own (PhD) activities in the PEP++ Project.
monthly scientific monitoring meetings with the field staff.
and submit quarterly progress reports and an annual progress report on own work
to the Project Coordinator and PhD supervisors.
and help supervise PEP++ field staff in technical aspects of their work during
regular field visits.
out own field research.
in and monitor the data collection in the project areas and to assist in
maintaining the database (including regular backups) in liaison with the local
health authorities and ErMC.
out research duties while spending time in the Netherlands each year.
networking with other organisations working with leprosy in the country.
in relevant field (MPH, MSc) with minimum 5 (five) years experiences in
research and demonstrable health program/project management.
experience in operational research.
to analyze and interpret data.
in written and spoken English is essential.
skills (MS Word, Excel, Power Point, internet, Epi-info, SPSS, etc.).
letter together with updated CV and reference letters should be submitted via